Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2017, Article ID 5642704, 8 pages
https://doi.org/10.1155/2017/5642704
Clinical Study

Effect of Prior Atorvastatin Treatment on the Frequency of Hospital Acquired Pneumonia and Evolution of Biomarkers in Patients with Acute Ischemic Stroke: A Multicenter Prospective Study

1Department of Critical Care Medicine, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200001, China
2Department of Emergency, Ruijin Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200025, China
3Department of Emergency, Minhang District Central Hospital, Shanghai 201100, China

Correspondence should be addressed to Chunyan Liu; moc.anis@yclrotcod and Yuan Gao; moc.anis@neruhznauyoag

Received 12 July 2016; Revised 23 December 2016; Accepted 4 January 2017; Published 5 March 2017

Academic Editor: Fabrizio Montecucco

Copyright © 2017 Yuetian Yu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. Torres, S. Ewig, H. Lode, and J. Carlet, “Defining, treating and preventing hospital acquired pneumonia: European perspective,” Intensive Care Medicine, vol. 35, no. 1, pp. 9–29, 2009. View at Publisher · View at Google Scholar · View at Scopus
  2. N. Anand and M. H. Kollef, “The alphabet soup of pneumonia: CAP, HAP, HCAP, NHAP, and VAP,” Seminars in Respiratory and Critical Care Medicine, vol. 30, no. 1, pp. 3–9, 2009. View at Publisher · View at Google Scholar · View at Scopus
  3. M. J. Richards, J. R. Edwards, D. H. Culver, and R. P. Gaynes, “Nosocomial infections in medical intensive care units in the United States,” Critical Care Medicine, vol. 27, no. 5, pp. 887–892, 1999. View at Publisher · View at Google Scholar · View at Scopus
  4. W. A. Van Klei and W. F. Buhre, “Anti-inflammatory effects of perioperative statin therapy,” Canadian Journal of Anesthesia, vol. 59, no. 6, pp. 516–521, 2012. View at Publisher · View at Google Scholar · View at Scopus
  5. M. K. Jain and P. M. Ridker, “Anti-inflammatory effects of statins: clinical evidence and basic mechanisms,” Nature Reviews Drug Discovery, vol. 4, no. 12, pp. 977–987, 2005. View at Publisher · View at Google Scholar · View at Scopus
  6. Y. Almog, A. Shefer, V. Novack et al., “Prior statin therapy is associated with a decreased rate of severe sepsis,” Circulation, vol. 110, no. 7, pp. 880–885, 2004. View at Publisher · View at Google Scholar · View at Scopus
  7. R. G. Schlienger, D. S. Fedson, S. S. Jick, H. Jick, and C. R. Meier, “Statins and the risk of pneumonia: A Population-based, Nested Case-control Study,” Pharmacotherapy, vol. 27, no. 3, pp. 325–332, 2007. View at Publisher · View at Google Scholar · View at Scopus
  8. E. M. W. van de Garde, E. Hak, P. C. Souverein, A. W. Hoes, J. M. M. van den Bosch, and H. G. M. Leufkens, “Statin treatment and reduced risk of pneumonia in patients with diabetes,” Thorax, vol. 61, no. 11, pp. 957–961, 2006. View at Publisher · View at Google Scholar · View at Scopus
  9. S. R. Majumdar, F. A. McAlister, D. T. Eurich, R. S. Padwal, and T. J. Marrie, “Statins and outcomes in patients admitted to hospital with community acquired pneumonia: Population Based Prospective Cohort Study,” British Medical Journal, vol. 333, no. 7576, pp. 999–1001, 2006. View at Publisher · View at Google Scholar · View at Scopus
  10. J. Bamford, P. Sandercock, M. Dennis, C. Warlow, and J. Burn, “Classification and natural history of clinically identifiable subtypes of cerebral infarction,” The Lancet, vol. 337, no. 8756, pp. 1521–1526, 1991. View at Publisher · View at Google Scholar · View at Scopus
  11. K. L. Furie, S. E. Kasner, R. J. Adams et al., “Guidelines for the prevention of stroke in patients with stroke or transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association,” Stroke, vol. 42, no. 1, pp. 227–276, 2011. View at Publisher · View at Google Scholar
  12. E. C. Jauch, J. L. Saver, H. P. Adams et al., “Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association,” Stroke, vol. 44, no. 3, pp. 870–947, 2013. View at Publisher · View at Google Scholar · View at Scopus
  13. S. C. Fagan, “Urgent need for secondary stroke prevention after transient ischemic attack,” Consultant Pharmacist, vol. 23, no. 2, pp. 131–140, 2008. View at Publisher · View at Google Scholar · View at Scopus
  14. S. M. Davis and G. A. Donnan, “Clinical practice. Secondary prevention after ischemic stroke or transient ischemic attack,” The New England Journal of Medicine, vol. 366, no. 20, pp. 1914–1922, 2012. View at Google Scholar
  15. R. Ji, G. Liu, H. Shen et al., “Persistence of secondary prevention medications after acute ischemic stroke or transient ischemic attack in Chinese population: data from China National Stroke Registry,” Neurological Research, vol. 35, no. 1, pp. 29–36, 2013. View at Publisher · View at Google Scholar · View at Scopus
  16. P. S. Kruger, N. M. Freir, B. Venkatesh, T. A. Robertson, M. S. Roberts, and M. Jones, “A preliminary study of atorvastatin plasma concentrations in critically ill patients with sepsis,” Intensive Care Medicine, vol. 35, no. 4, pp. 717–721, 2009. View at Publisher · View at Google Scholar · View at Scopus
  17. American Thoracic Society and Infectious Diseases Society of America, “Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia,” American Journal of Respiratory and Critical Care Medicine, vol. 171, no. 4, pp. 388–416, 2005. View at Publisher · View at Google Scholar
  18. J. Muscedere, P. Dodek, S. Keenan, R. Fowler, D. Cook, and D. Heyland, “Comprehensive evidence-based clinical practice guidelines for ventilator-associated pneumonia: diagnosis and treatment,” Journal of Critical Care, vol. 23, no. 1, pp. 138–147, 2008. View at Publisher · View at Google Scholar · View at Scopus
  19. J. Muscedere, P. Dodek, S. Keenan, R. Fowler, D. Cook, and D. Heyland, “Comprehensive evidence-based clinical practice guidelines for ventilator-associated pneumonia: prevention,” Journal of Critical Care, vol. 23, no. 1, pp. 126–137, 2008. View at Publisher · View at Google Scholar · View at Scopus
  20. British Thoracic Society Bronchoscopy Guidelines Committee, “British Thoracic Society guidelines on diagnostic flexible bronchoscopy,” Thorax, vol. 56, supplement 1, pp. i1–i21, 2001. View at Google Scholar
  21. D. Makris, E. Manoulakas, A. Komnos et al., “Effect of pravastatin on the frequency of ventilator-associated pneumonia and on intensive care unit mortality: open-label, randomized study,” Critical Care Medicine, vol. 39, no. 11, pp. 2440–2446, 2011. View at Publisher · View at Google Scholar · View at Scopus
  22. A. Rezaie-Majd, T. Maca, R. A. Bucek et al., “Simvastatin reduces expression of cytokines interleukin-6, interleukin-8, and monocyte chemoattractant protein-1 in circulating monocytes from hypercholesterolemic patients,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 22, no. 7, pp. 1194–1199, 2002. View at Publisher · View at Google Scholar · View at Scopus
  23. M. Z. Chaudhry, J. H. Wang, S. Blankson, and H. P. Redmond, “Statin (cerivastatin) protects mice against sepsis-related death via reduced proinflammatory cytokines and enhanced bacterial clearance,” Surgical Infections, vol. 9, no. 2, pp. 183–194, 2008. View at Publisher · View at Google Scholar · View at Scopus
  24. P. Kruger, M. Bailey, R. Bellomo et al., “A multicenter randomized trial of atorvastatin therapy in intensive care patients with severe sepsis,” American Journal of Respiratory and Critical Care Medicine, vol. 187, no. 7, pp. 743–750, 2013. View at Publisher · View at Google Scholar · View at Scopus
  25. P. S. Kruger, M. L. Harward, M. A. Jones et al., “Continuation of statin therapy in patients with presumed infection: a randomized controlled trial,” American Journal of Respiratory and Critical Care Medicine, vol. 183, no. 6, pp. 774–781, 2011. View at Publisher · View at Google Scholar · View at Scopus
  26. M. Nguile-Makao, J.-R. Zahar, A. Français et al., “Attributable mortality of ventilator-associated pneumonia: respective impact of main characteristics at ICU admission and VAP onset using conditional logistic regression and multi-state models,” Intensive Care Medicine, vol. 36, no. 5, pp. 781–789, 2010. View at Publisher · View at Google Scholar · View at Scopus
  27. M. B. Fessler, S. K. Young, S. Jeyaseelan et al., “A role for hydroxy-methylglutaryl coenzyme A reductase in pulmonary inflammation and host defense,” American Journal of Respiratory and Critical Care Medicine, vol. 171, no. 6, pp. 606–615, 2005. View at Publisher · View at Google Scholar · View at Scopus
  28. T. R. Craig, M. J. Duffy, M. Shyamsundar et al., “A randomized clinical trial of hydroxymethylglutaryl- coenzyme a reductase inhibition for acute lung injury (The HARP Study),” American Journal of Respiratory and Critical Care Medicine, vol. 183, no. 5, pp. 620–626, 2011. View at Publisher · View at Google Scholar
  29. J. Van Snick, “Interleukin-6: an overview,” Annual Review of Immunology, vol. 8, pp. 253–278, 1990. View at Publisher · View at Google Scholar · View at Scopus
  30. H. Wang, K. Zhang, L. Zhao, J. Tang, L. Gao, and Z. Wei, “Anti-inflammatory effects of vinpocetine on the functional expression of nuclear factor-kappa B and tumor necrosis factor-alpha in a rat model of cerebral ischemia-reperfusion injury,” Neuroscience Letters, vol. 566, pp. 247–251, 2014. View at Publisher · View at Google Scholar · View at Scopus